Recent Pfizer Press Releases

  • 9/3/15 5:17 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. ("Pfizer") (NYSE:PFE) announced today that it has commenced offers to exchange any and all validly tendered and accepted notes of the following series issued by Hospira, Inc. ("Hospira"), our recently acquired subsidiary, for new notes to be issued by Pfizer as described in the table below. A Registration Statement on Form S-4 (the "Registration Statement") relating to the issuance of the Pfizer Notes (as defined below) was filedmore...
  • 9/3/15 9:00 am EDT
    • Creates a leading Global Established Pharmaceutical (GEP) Business
    • Expected to be immediately accretive to adjusted diluted EPS1 upon closing; $0.10-$0.12 accretion to adjusted diluted EPS expected in first full year after close with additional accretion anticipated thereafter
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of Hospira, Inc. “We are pleased that Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, is now part of Pfizer. We want to welcome our new Hospira colleagues to Pfizer. We are excited to add their talents and proud of the shared commitment of all Pfizer colleagues to serving patients worldwidemore...
  • 8/26/15 7:30 am EDT

    Partnership with Pfizer, BIG, GBG, NSABP and PrECOG to facilitate further investigation of IBRANCE

    NEW YORK--(BUSINESS WIRE)--The Alliance Foundation Trials, LLC (AFT), the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and Pfizer Inc. today announced the launch of the Palbociclib Collaborative Adjuvant Study, or PALLAS. This global Phase 3 clinical trial for patients with early-stage breast cancer is being conducted in conjunction with Breast International Group (BIG), German Breast Group (GBG), National Surgical Adjuvant Breast and Bowel Project (more...
  • 8/24/15 8:15 am EDT
    • Twenty-two abstracts to be presented, including new analyses from ARISTOTLE and real-world data analyses evaluating the risk of major bleeding, bleeding-related hospital readmissions, hospitalization rates and healthcare costs among patients with nonvalulvar atrial fibrillation (NVAF) receiving novel oral anticoagulant (NOACs)
    • Results from the AEGEAN (Assessment of an Educational and Guidance Programme for Eliquis Adherence in Nonvalvular Atrial Fibrillation) study will also be presented as a late-breaking trial
    PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced today that 22 abstracts (late-breaking, rapid-fire, oral and poster presentations) will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance’s commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE)more...
  • 8/24/15 8:00 am EDT
    • FTC Consent Order includes agreement to divest four sterile injectable assets
    • Brazil’s Superintendency-General of the Council for Economic Defense (CADE) has published its unconditional clearance decision
    • Transaction expected to close in early September 2015
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Hospira (NYSE:HSP). The FTC’s clearance is contingent upon Pfizer’s commitment to divest four U.S. sterile injectable assets, including Acetylcysteine, Clindamycin, Voriconazole and Melphalan. Inmore...
  • 8/21/15 8:00 am EDT

    Data Consistent with Immunogenicity and Safety Data from Previous Studies

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today positive topline results of two Phase 3 studies of TRUMENBA® (Meningococcal Group B Vaccine). One study included approximately 3,600 healthy individuals 10 through 18 years of age, and the other study included approximately 3,300 healthy individuals 18 through 25 years of age. Both studies met all primary immunogenicity endpoints, demonstrating robust immune responses against certain invasive meningococcalmore...
  • 8/20/15 11:23 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for IBRANCE® (palbociclib) in combination with endocrine therapy for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. With this validation, the Pfizer application is complete and the EMA will now begin the reviewmore...
  • 8/14/15 8:35 am EDT

    Approval Includes Certain Commitments

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it was granted approval from the Canadian Competition Bureau with respect to its pending acquisition of Hospira (NYSE: HSP). As part of its agreement with the Canadian Competition Bureau, Pfizer has committed to divest certain assets in Canada. “We are pleased the Canadian Competition Bureau concluded its review of the transaction and approved the pending combination of Pfizer andmore...
  • 8/13/15 8:15 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the Australian Competition and Consumer Commission (ACCC) has approved the company’s pending acquisition of Hospira, Inc. (NYSE:HSP) and found no need for remedies. “We are pleased to have achieved another significant milestone for Pfizer’s pending acquisition of Hospira with the ACCC’s approval of the transaction,” said Ian Read, chairman and chief executive officer, Pfizer. “We continue tomore...
  • 8/4/15 11:36 am EDT

    European Commission Approval Includes Certain Commitments

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company’s pending acquisition of Hospira, Inc. (NYSE: HSP). The Commission's decision includes Pfizer’s commitment to divest certain assets. “We are pleased to have achieved a significant milestone for Pfizer’s pending acquisition of Hospira with the EC’s approval of the transaction,” said Ianmore...